ACTIVE SESSION TAPE Biotechnology $2.08B Cap Quant: AVOID NEW MONEY

Why Is Mesoblast Limited (MESO) Stock Down Today?

Updated Nov 16, 2026 2:29 PM ET · Prev Close $13.27

Pro Workspace
Last Session Price
$12.47 -6.03%
-$0.80 vs $13.27 prior close
Intraday Range
$12.40 – $13.02
Open $13.02
Relative Volume
0.29x Avg
77,389 sh
52-Week Range
$11.89 – $21.50
Benchmark Alpha
-4.14% vs SPY
-3.61% vs QQQ
20-Session Trend +0.5%

Session Regime & Catalyst Assessment

68% Signal Conviction
TECHNICAL 68% Driver Weight

Mesoblast Limited Pulling Back 6.03% on 0.29x Relative Volume

Mesoblast Limited (MESO) is pulling back 6.03% (-$0.80) to $12.47 on 0.29x average session volume. Relative to benchmarks, MESO is lagging the S&P 500 by -4.14%. 14-day RSI stands at 39.0, keeping momentum in a bearish regime.

NEWS 70% Weight
Mesoblast Showcased at ASX Premier Investor Day Event

New York, Nov. 15, 2026 Globe Newswire -- Mesoblast Limited Nasdaq Meso Asx Msb , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($12.47) trades relative to 20-day SMA ($13.64) and 50-day SMA ($14.22).

Volume Confirmation
LOW VOLUME (0.29x) Consolidation
Sub-average participation — monitor RVOL expansion above 1.2x.
Composite Catalyst Confidence 68%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

MESO lagging the S&P 500 by -4.14%
MESO Session
-6.03%
$12.47
S&P 500 (SPY)
-1.89%
$740.11
Nasdaq 100 (QQQ)
-2.42%
$663.44
Healthcare (XLV)
-0.38%
$188.14
Alpha vs SPY: -4.14% Alpha vs QQQ: -3.61% Alpha vs XLV: -5.65%

Options Flow & Execution Desk

Recent MESO Catalyst Headlines

Verified Wire
Mesoblast Showcased at ASX Premier Investor Day Event

New York, Nov. 15, 2026 Globe Newswire -- Mesoblast Limited Nasdaq Meso Asx Msb , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities

Yahoo Finance · Nov 15, 2026
Top 3 Australian Founder Led Stocks To Watch In November 2026

Rising refinancing costs in a world hit by a new credit crunch are putting pressure on heavily indebted companies, while investors increasingly favour businesses with cleaner balance sheets and clear leadership. Founder

Yahoo Finance · Nov 15, 2026
3 Australian Growth Stocks To Own In November 2026

AI related infrastructure is now driving a large share of global trade, with AI enabling goods responsible for most of the recent growth in worldwide shipments. That kind of structural shift tends to reward fast growing

Yahoo Finance · Nov 13, 2026

1–3 Day Expected Range & Key Level

48% Follow-Through
Lower Bound
$11.78
Short-term support band
Upper Bound
$13.16
Short-term resistance band
Key Inflection Level
$13.64 (20-day SMA resistance)

Monitor volume expansion above 1.5x RVOL around $13.64 (20-day SMA resistance) for directional breakout confirmation.

Technical Regime (MESO)

BEARISH MA TREND
RSI (14)
39.0
Bearish
20-Day SMA
$13.64
Below 20d
50-Day SMA
$14.22
Below 50d
MACD Signal
Bearish
MACD -0.24
ADX (14)
15.8
Weak trend
10d Momentum
-1.95
Soft 10-day momentum

Retail & Crowd Sentiment

Bullish
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Reddit communities: 1 comment (Bullish)

About Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory …

Sector
Healthcare
Market Cap
$2.08B
Forward P/E
454.5x
Employees
81

Get Instant MESO Catalyst Alerts

Receive an email alert when MESO triggers an unusual volume breakout, options sweep, or rating shift.

Other Liquid Stocks Moving Today

All Today's Movers

MESO Session & Catalyst FAQ

Why is MESO stock down today?

Mesoblast Limited (MESO) is pulling back 6.03% (-$0.80) to $12.47 on 0.29x average session volume. Relative to benchmarks, MESO is lagging the S&P 500 by -4.14%. 14-day RSI stands at 39.0, keeping momentum in a bearish regime.

Is MESO stock a buy or sell right now?

Today's session carries a 68% catalyst conviction score on 0.29x relative volume (low participation). Our multi-factor model currently rates MESO as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the MESO Buy or Sell Decision Brief →

What is MESO's intrinsic value and expected trading range?

At $12.47, MESO's modeled 1-to-3 session range is $11.78 – $13.16, with a key inflection level at $13.64 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the MESO Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →

What do RSI and moving averages signal for MESO?

RSI at 39.0 reflects soft below-midline momentum. MESO trades at $12.47 relative to its 20-day SMA ($13.64) and 50-day SMA ($14.22), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs